Imaeda et al 28 | ADAbs+ | ADAbs− | Total | Population and anti-TNFα therapy; tests |
Anti-TNFα− | LOR=8 | LOR=2 | LOR=10 | Responders on adalimumab maintenance; ELISA. Prevalence of LOR=37.5% |
RESP=0 | RESP=2 | RESP=2 | ||
Anti-TNFα+ | LOR=2 | LOR=3 | LOR=5 | |
RESP=4 | RESP=19 | RESP=23 | ||
Total | LOR=10 | LOR=5 | LOR=15 | |
RESP=4 | RESP=21 | RESP=25 |
The probability of a patient returning each of the four possible test result combinations was:
ADAbs+/anti-TNFα−, 0.200; ADAbs+/anti-TNFα+, 0.150; ADAbs−/anti-TNFα−, 0.10; ADAbs−/anti-TNFα+, 0.550.
The probabilities of losing response according to the category of test result were 1.00, 0.333, 0.500 and 0.136, respectively.
ADAbs, antidrug antibodies; ; LOR, loss of response; RESP, responders; ; TNF, tumour necrosis factor.